GPT and fibrosis: In summary, the current study suggests that when using non-invasive tests to screen for advanced fibrosis (FIB-4, NFS, or APRI) in overweight and obese patients, targeted screening of patients with elevated ALT provides the most cost-effective approach, reducing the number of needed biopsies while maintaining the sensitivity.